ZA201101449B - Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic - Google Patents

Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic

Info

Publication number
ZA201101449B
ZA201101449B ZA2011/01449A ZA201101449A ZA201101449B ZA 201101449 B ZA201101449 B ZA 201101449B ZA 2011/01449 A ZA2011/01449 A ZA 2011/01449A ZA 201101449 A ZA201101449 A ZA 201101449A ZA 201101449 B ZA201101449 B ZA 201101449B
Authority
ZA
South Africa
Prior art keywords
antiepileptic
dimethylamino
phenol
propyl
ethyl
Prior art date
Application number
ZA2011/01449A
Other languages
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Thomas Christoph
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201101449(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of ZA201101449B publication Critical patent/ZA201101449B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2011/01449A 2008-09-05 2011-02-23 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic ZA201101449B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
PCT/EP2009/006424 WO2010025931A2 (en) 2008-09-05 2009-09-04 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
ZA201101449B true ZA201101449B (en) 2011-10-26

Family

ID=40345058

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/01449A ZA201101449B (en) 2008-09-05 2011-02-23 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic

Country Status (28)

Country Link
US (1) US20100063148A1 (cg-RX-API-DMAC10.html)
EP (2) EP2331210B1 (cg-RX-API-DMAC10.html)
JP (4) JP5731387B2 (cg-RX-API-DMAC10.html)
KR (3) KR101641519B1 (cg-RX-API-DMAC10.html)
CN (2) CN102159284B (cg-RX-API-DMAC10.html)
AR (2) AR073361A1 (cg-RX-API-DMAC10.html)
AU (3) AU2009289776A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0920521A2 (cg-RX-API-DMAC10.html)
CA (1) CA2735857C (cg-RX-API-DMAC10.html)
CL (1) CL2011000317A1 (cg-RX-API-DMAC10.html)
CO (1) CO6382142A2 (cg-RX-API-DMAC10.html)
CY (2) CY1115751T1 (cg-RX-API-DMAC10.html)
DK (2) DK2331210T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP11010869A (cg-RX-API-DMAC10.html)
ES (2) ES2513394T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20140663T1 (cg-RX-API-DMAC10.html)
HU (1) HUE043278T2 (cg-RX-API-DMAC10.html)
IL (3) IL211135A (cg-RX-API-DMAC10.html)
LT (1) LT2735338T (cg-RX-API-DMAC10.html)
MX (1) MX2011002339A (cg-RX-API-DMAC10.html)
PE (5) PE20142372A1 (cg-RX-API-DMAC10.html)
PL (2) PL2331210T3 (cg-RX-API-DMAC10.html)
PT (2) PT2735338T (cg-RX-API-DMAC10.html)
RU (2) RU2571501C2 (cg-RX-API-DMAC10.html)
SI (2) SI2331210T1 (cg-RX-API-DMAC10.html)
TR (1) TR201904388T4 (cg-RX-API-DMAC10.html)
WO (1) WO2010025931A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201101449B (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EA019757B1 (ru) * 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
PL2680833T3 (pl) * 2011-03-04 2016-08-31 Gruenenthal Gmbh Pozajelitowe podawanie tapentadolu
EP2753302B1 (en) * 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
EP3300726A1 (en) * 2011-07-29 2018-04-04 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
BR112015009839A2 (pt) * 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd composição farmacêutica de tapentadol para administração parenteral
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
DK3800177T3 (da) 2015-12-22 2025-03-31 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CN102675136B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
MX2010005680A (es) * 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
CA2710538A1 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination

Also Published As

Publication number Publication date
JP2019131578A (ja) 2019-08-08
IL237391A0 (en) 2015-04-30
AU2009289776A1 (en) 2010-03-11
IL211135A (en) 2017-09-28
KR101730924B1 (ko) 2017-04-27
EP2735338B1 (en) 2019-02-06
JP2017071636A (ja) 2017-04-13
HK1198145A1 (en) 2015-03-13
DK2735338T3 (en) 2019-04-23
CN102159284B (zh) 2015-12-09
PE20142357A1 (es) 2015-02-04
JP2012501986A (ja) 2012-01-26
AU2016203053A1 (en) 2016-06-02
PE20110291A1 (es) 2011-06-04
IL237391A (en) 2017-12-31
PL2331210T3 (pl) 2014-12-31
ES2719900T3 (es) 2019-07-16
PT2331210E (pt) 2014-08-25
IL237392B (en) 2019-08-29
RU2674150C1 (ru) 2018-12-05
SI2735338T1 (sl) 2019-04-30
CL2011000317A1 (es) 2011-06-17
JP5731387B2 (ja) 2015-06-10
CA2735857C (en) 2019-05-28
EP2331210B1 (en) 2014-07-09
BRPI0920521A2 (pt) 2018-01-16
CN105520924A (zh) 2016-04-27
AR073361A1 (es) 2010-11-03
CY1121492T1 (el) 2020-05-29
RU2571501C2 (ru) 2015-12-20
KR20160086981A (ko) 2016-07-20
TR201904388T4 (tr) 2019-05-21
HK1159011A1 (en) 2012-07-27
WO2010025931A2 (en) 2010-03-11
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
DK2331210T3 (da) 2014-08-11
CY1115751T1 (el) 2017-01-25
KR20170048602A (ko) 2017-05-08
ES2513394T3 (es) 2014-10-27
CO6382142A2 (es) 2012-02-15
CN102159284A (zh) 2011-08-17
PE20142371A1 (es) 2015-02-04
HUE043278T2 (hu) 2019-08-28
US20100063148A1 (en) 2010-03-11
PT2735338T (pt) 2019-05-24
AU2016203053B2 (en) 2018-01-25
IL237392A0 (en) 2015-04-30
HRP20190500T1 (hr) 2019-08-09
CN105520924B (zh) 2019-04-09
JP2015096530A (ja) 2015-05-21
MX2011002339A (es) 2011-04-04
IL211135A0 (en) 2011-04-28
AU2018202879B2 (en) 2020-03-12
CA2735857A1 (en) 2010-03-11
ECSP11010869A (es) 2011-04-29
AU2018202879A1 (en) 2018-05-17
HRP20140663T1 (hr) 2014-10-10
AR117613A2 (es) 2021-08-18
EP2735338A1 (en) 2014-05-28
PL2735338T3 (pl) 2019-07-31
KR20110057144A (ko) 2011-05-31
SI2331210T1 (sl) 2014-10-30
EP2331210A2 (en) 2011-06-15
PE20190914A1 (es) 2019-06-26
PE20142372A1 (es) 2015-02-04
RU2011112444A (ru) 2012-10-10
WO2010025931A3 (en) 2010-06-17
KR101641519B1 (ko) 2016-07-21

Similar Documents

Publication Publication Date Title
IL237391A (en) Combination of 3 - (3 Dimethylamino - 1 - Ethyl - 2 - Methyl - Profile) - Phenol and Epilepsy
GB2456813B (en) Diagnostic context construction and comparison
IL212986A (en) Double-stranded oligonucleotide and a pharmaceutical composition
IL243015B (en) Polycyclic compounds and pharmaceutical preparations containing them
IL211785A0 (en) CO-CRYSTALS OF TRAMADOL AND NSAIDs
BRPI0909750A2 (pt) dispositivo e cápsula para a preparação de uma bebida
IL217774A0 (en) Compositions for treating gaucher disease and uses thereof
IL218016A0 (en) Pharmaceutical compositions comprising bi-1356 and metformin
EP2449102A4 (en) ARGINASE FORMULATIONS AND METHODS
PT2474522E (pt) Agomelatina e composições farmacêuticas que contêm a mesma
GB201014075D0 (en) Risk and reward assessment mechanism
ZA201200079B (en) Pharmaceutical compositions and solid forms
ZA201201892B (en) Co-crystals of tramadol and coxibs
ZA201102682B (en) Aptamer for agf and use thereof
IL201247A0 (en) Combinations of statins and anti-obesity agent
IL219963A (en) Pharmaceutical composition containing transcorsorcaline hydrochloride and mannitol and its use
EP2322608A4 (en) TRANSFECTION AGENT
EP2232192A4 (en) QUICK AND EASY TO INSTALL CASE
PL2236145T3 (pl) Kompozycja farmaceutyczna i lek złożony
ZA201100529B (en) Solid pharmaceutical composition comprising exemestane
PL2488169T3 (pl) Kokryształy tramadolu i koksybów
TWM365670U (en) An object structure capable of keeping fragrance
GB0902648D0 (en) Pharmaceutical compounds and compositions
BRPI1009131A2 (pt) composição farmacêutica compreendendo aliscireno
HK1155261A (en) Risk and reward assessment mechanism